Skip to main content

Health Care Industry

Featured Article
Ineffective language is creating barriers in health insurance coverage for the 65 year and older population, according to a report released by VisibleThread, a content analysis company that…
In this expert commentary, Steven Lieberman, MD, acting principal deputy under secretary for health at the Veterans Health Administration, explains the history of wait times within the VA and…

Insights

Nina Jain, MD, MBA and colleagues analyzed how the proposed changes to shift certain drugs from Medicare Part B to Part D will save costs for payers and patients.
While the nation undergoes turbulent times surrounding illegal immigration, New York City and California are offering plans to cover undocumented immigrants. First Report Managed Care reached out to its panel of experts for their take on these new…
Peter Pitts, former associate commissioner with the FDA and president of the Center for Medicine in the Public Interest, discusses recent agreements finalized by the White House, United States, Mexico, and Canada, and he explains why this new trade…
Seth Freedman, PhD, assistant professor at Indiana University School of Public and Environmental Affairs and economist who studies innovations in the health care system, discusses trends in health care, including changes in the structure of firms…

Interactive Features

In this expert commentary, Steven Lieberman, MD, acting principal deputy under secretary for health at the Veterans Health Administration, explains the history of wait times within the VA and discusses how they have improved in recent years and why…
Do you think the VA and Department of Homeland Security's recent partnership will help lower suicide rates among veterans?
ResMed, known for its cloud-connected medical devices and out-of-hospital software-as-a-service business solutions, has recently announced it has completed its acquisition of Propeller Health. Tell us if you think this move is beneficial. 
In this podcast, Parag Joshi, MD, discusses the 2018 cholesterol guidelines and how these cholesterol-lowering drugs can be used in practice. He also discusses the cost-effectiveness of PCSK9 inhibitors.
Back to Top